Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
Authors:
Open Access
- 29 June 2023
- journal article
- review article
- Published by Springer Nature in Neurology and Therapy
- Vol. 12 (5) , 1457-1476
Abstract
Cladribine tablets (CladT) is a highly active oral disease-modifying therapy (DMT) for the management of relapsing multiple sclerosis (RMS). CladT acts as an immune reconstitution therapy, in that two short courses of treatment 1 year apart have been shown to suppress disease activity for a prolonged period in most patients, without need for continued DMT. Each course of CladT induces a profound reduction in B lymphocytes that recovers over months, and serious lymphopenia (Grade 3–4) is uncommon. Smaller reductions in levels of T lymphocytes occur slightly later: on average, these remain within the normal range and repopulate progressively. A larger effect occurs on CD8 vs. CD4 cells. Reactivation of latent or opportunistic infections (e.g. varicella zoster, tuberculosis) is mostly associated with very low lymphocyte counts (< 200/mm3). Screening and managing pre-existing infections, vaccinating non-exposed patients and delaying the 2nd year of treatment with CladT to allow lymphocytes to recover to > 800/mm3 (if necessary) are important for avoiding infections and higher-grade lymphopenia. There was no demonstrable or apparent effect of CladT on the efficacy of vaccinations, including against Covid-19. Adverse events consistent with drug-induced liver injury (DILI) represent a rare but potentially serious complication of CladT therapy in spontaneous adverse event reporting; patients should be screened for liver dysfunction before starting treatment. Ongoing hepatic monitoring is not required, but CladT must be withdrawn if signs and symptoms of DILI develop. There was a numerical imbalance for malignancies when comparing cladribine to placebo in the clinical programme, particularly in short-term data, but recent evidence shows that the risk of malignancy with CladT is similar to the background rate in the general population and to that with other DMTs. Overall, CladT is well tolerated with a favorable safety profile appropriate for the management of RMS.Keywords
This publication has 80 references indexed in Scilit:
- Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid—Results from the ToFingo Successor StudyFrontiers in Immunology, 2018
- 040 An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2018
- Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosisCurrent Medical Research and Opinion, 2017
- Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY studyMultiple Sclerosis Journal, 2017
- Alemtuzumab improves preexisting disability in active relapsing-remitting MS patientsNeurology, 2016
- No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribineNeurology Neuroimmunology & Neuroinflammation, 2015
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialThe Lancet, 2012
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialThe Lancet, 2012
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- The Clinical Pharmacokinetics of CladribineClinical Pharmacokinetics, 1997